Cargando…
Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation
Celecoxib (CLB) is a highly hydrophobic selective cyclo-oxygenase inhibitor with high plasma protein binding and undergoes extensive hepatic metabolism. CLB is highly effective in the treatment of osteo and rheumatoid arthritis as first line therapy but produces severe gastro-intestinal toxicities a...
Autores principales: | Begum, M. Yasmin, M. Osmani, Riyaz Ali, Alqahtani, Ali, Ghazwani, Mohammed, Hani, Umme, Ather, Hissana, Atiya, Akhtar, Rahamathulla, Mohamed, Siddiqua, Ayesha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041753/ https://www.ncbi.nlm.nih.gov/pubmed/35472207 http://dx.doi.org/10.1371/journal.pone.0264518 |
Ejemplares similares
-
Novel Drug Delivery Systems as an Emerging Platform for Stomach Cancer Therapy
por: Hani, Umme, et al.
Publicado: (2022) -
Development and Evaluation of Solid Lipid Nanoparticles for the Clearance of Aβ in Alzheimer’s Disease
por: Shivananjegowda, Meghana Goravinahalli, et al.
Publicado: (2023) -
Development and Characterization of Oral Raft Forming In Situ Gelling System of Neratinib Anticancer Drug Using 3(2) Factorial Design
por: Hani, Umme, et al.
Publicado: (2022) -
Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review
por: Alhamhoom, Yahya, et al.
Publicado: (2023) -
Carvedilol Precipitation Inhibition by the Incorporation of Polymeric Precipitation Inhibitors Using a Stable Amorphous Solid Dispersion Approach: Formulation, Characterization, and In Vitro In Vivo Evaluation
por: Ravikumar, Akhila Akkihebbal, et al.
Publicado: (2022)